Piperazinylcarbonylquinolines and -isoquinolines

US7329749B2 · kind B2 · utility

Assignee

• Merck Patentgesellschaft · DE

Inventors

• Henning Boettcher · Darmstadt, DE
• Gerd Bartoszyk · Weiterstadt, DE
• Juergen Harting · Darmstadt, DE
• Christoph van Amsterdam · Darmstadt, DE
• Christoph Seyfried · Seeheim-Jugenheim, DE

Key dates

• Filing date: Dec 24, 2001
• Grant date: Feb 12, 2008
• Expiry date: Feb 28, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D217/26
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compound of the formula (I) in which R1, R2 and alk are as defined in Claim 1, are potent 5-HT2A antagonist and are suitable for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Hutington's disease, eating disorders, such as bulimia, anorexia nervosa, premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder (OCD).